Press Releases

03 April 2023
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
10 March 2023
Sumitovant Biopharma Completes Acquisition of Myovant Sciences
26 January 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
16 November 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 November 2022
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources
26 October 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
24 October 2022
Myovant Sciences Cancels Second Quarter Earnings Conference Call
23 October 2022
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
18 October 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
14 October 2022
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on October 26, 2022
02 October 2022
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
16 September 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
16 September 2022
Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
02 September 2022
Myovant Sciences to Participate at Upcoming Investor Conferences
16 August 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
05 August 2022
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
27 July 2022
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
18 July 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
13 July 2022
Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
17 June 2022
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
16 June 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
03 June 2022
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
02 June 2022
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
10 May 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
09 May 2022
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
06 May 2022
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
29 April 2022
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
26 April 2022
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
12 April 2022
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
25 February 2022
Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX® (relugolix) for the Treatment of Advanced Prostate Cancer
07 February 2022
Myovant Sciences to Present at Upcoming Investor Conferences
26 January 2022
Myovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
12 January 2022
Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
10 January 2022
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
03 January 2022
Myovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
23 November 2021
Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
08 November 2021
Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors
26 October 2021
Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
19 October 2021
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
12 October 2021
Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
09 September 2021
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
01 September 2021
Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference
12 August 2021
Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer
28 July 2021
Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates
20 July 2021
Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
14 July 2021
Myovant Sciences to Host First Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on July 28, 2021
01 June 2021
Myovant Sciences to Present at Upcoming Investor Conferences
26 May 2021
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
21 May 2021
Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
11 May 2021
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2021
04 May 2021
Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on May 11, 2021
12 April 2021
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet
05 April 2021
Myovant Sciences Appoints Lauren Merendino as Chief Commercial Officer
29 March 2021
Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
24 March 2021
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
23 March 2021
Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
22 February 2021
Myovant Sciences to Present at Upcoming Investor Conferences
17 February 2021
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
17 February 2021
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
16 February 2021
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
11 February 2021
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
29 January 2021
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
26 January 2021
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
20 January 2021
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
05 January 2021
CORRECTION — Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
05 January 2021
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
04 January 2021
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
28 December 2020
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
18 December 2020
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
16 December 2020
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
23 November 2020
Myovant Sciences to Present at Upcoming December Investor Conferences
17 November 2020
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
12 November 2020
Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
02 November 2020
Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
21 October 2020
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
14 October 2020
Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
29 September 2020
Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
23 September 2020
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
14 September 2020
Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
17 August 2020
Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
11 August 2020
Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020
05 August 2020
Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
06 July 2020
Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
30 June 2020
BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
23 June 2020
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
22 June 2020
Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
22 June 2020
Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
01 June 2020
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
29 May 2020
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
18 May 2020
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
14 May 2020
Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
27 April 2020
Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
22 April 2020
Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
21 April 2020
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition
21 April 2020
Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
14 April 2020
Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
31 March 2020
Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
10 March 2020
Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
09 March 2020
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
25 February 2020
Myovant Sciences to Present at Upcoming March Investor Conferences
10 February 2020
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019
10 February 2020
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
06 January 2020
Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
30 December 2019
Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
25 November 2019
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
19 November 2019
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
18 November 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
12 November 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019
31 October 2019
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
21 October 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
17 October 2019
Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
17 October 2019
First-of-Its-Kind Nationwide Survey from Myovant Sciences and Evidation Health Captures Impact of Menstrual Stigma and Symptoms
10 October 2019
Myovant Sciences Announces Late-Breaking Oral Presentation of Phase 3 LIBERTY 1 & 2 Study Results at 2019 American Society for Reproductive Medicine Scientific Congress
06 September 2019
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
27 August 2019
CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
27 August 2019
Myovant Sciences to Participate in Upcoming September Investor Conferences
20 August 2019
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
06 August 2019
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
23 July 2019
Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
22 July 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
10 July 2019
Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
24 June 2019
Myovant Sciences to Present at Upcoming June Investor Conferences
30 May 2019
Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
29 May 2019
Myovant Sciences Announces $100 Million Public Offering of Common Shares
24 May 2019
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
14 May 2019
Myovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
13 May 2019
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroids
05 March 2019
Myovant Sciences to Present at Upcoming Investor Conferences
07 February 2019
Myovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018
20 December 2018
Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
15 November 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
08 November 2018
Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018
07 November 2018
Myovant Strengthens Management Team and Adds New Directors to the Board
24 October 2018
Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer
10 October 2018
Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress
08 October 2018
Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
28 August 2018
Myovant Sciences to Participate in Two Upcoming Investor Conferences
07 August 2018
Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018
12 July 2018
Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares
11 July 2018
Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares
10 July 2018
Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids
18 June 2018
Myovant Sciences to Present at First Annual Roivant Pipeline Day
07 June 2018
Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018
20 April 2018
Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation Around Period Health
06 March 2018
Myovant Sciences to Present at Upcoming Investor Conferences
13 February 2018
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
04 January 2018
Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
21 November 2017
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference
13 November 2017
Myovant Sciences Provides Corporate Update and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2017
09 November 2017
Myovant Sciences Announces Positive Top-line Results from Takeda’s Phase 3 Study Evaluating the Efficacy and Safety of Relugolix for the Treatment of Pain Associated with Uterine Fibroids
16 October 2017
Myovant Sciences Secures Flexible Financing Commitments of up to $140 Million
02 October 2017
Myovant Sciences Announces Positive Top-line Results from Takeda’s Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids
31 August 2017
Myovant Sciences Announces Upcoming Presentation at Baird’s 2017 Global Healthcare Conference
10 August 2017
Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017
19 July 2017
Myovant Bolsters Executive Team with Key Management Appointments
29 June 2017
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain
24 May 2017
Myovant Sciences Announces Presentation of Data at the European Congress of Endocrinology from Phase 2 Extension Study Evaluating Relugolix in Women with Endometriosis-Associated Pain
19 May 2017
Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Endometriosis-Associated Pain at the World Congress on Endometriosis
18 May 2017
Myovant Sciences Announces Upcoming Presentations of Relugolix Data from Phase 2 Trial in Women with Endometriosis-Associated Pain
07 May 2017
Myovant Sciences Announces Presentation of Positive Phase 2 Data for Relugolix in Women with Heavy Menstrual Bleeding and Uterine Fibroids at the Annual Meeting of the American Congress of Obstetricians and Gynecologists
01 March 2017
Myovant Sciences Initiates Phase 3 Clinical Trial of Relugolix in Men with Advanced Prostate Cancer
27 February 2017
Myovant Sciences to Present at Upcoming Investor Conferences
27 January 2017
Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
16 November 2016
Myovant Sciences Appoints Terrie Curran to Board of Directors
27 October 2016
Myovant Sciences Ltd. Announces Pricing of Initial Public Offering
12 October 2016
Myovant Sciences Announces Appointment of Board of Directors
06 June 2016
Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women’s Health and Prostate Cancer

You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.

Confirm Close